Open access
Open access
Powered by Google Translator Translator

Chest Medicine

RCT: Remdesivir does not improve outcomes in patients admitted to hospital with COVID-19.

15 Sep, 2021 | 09:59h | UTC

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial – The Lancet Infectious Diseases

Invited commentary: Remdesivir, on the road to DisCoVeRy – The Lancet Infectious Diseases

Related:

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

WHO Solidarity Trial: Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19

 

Review | Prevention of host-to-host transmission by SARS-CoV-2 vaccines.

15 Sep, 2021 | 09:16h | UTC

Prevention of host-to-host transmission by SARS-CoV-2 vaccines – The Lancet Infectious Diseases

Related:

Study ties COVID vaccines to lower transmission rates.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

 

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

15 Sep, 2021 | 09:07h | UTC

Ivermectin: Cochrane’s most talked about review so far, ever. Why? – Cochrane Library

Original review: Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

 

Commentary on Twitter

 

CDC report finds unvaccinated people are 11 times more likely to die of COVID-19.

15 Sep, 2021 | 09:09h | UTC

Unvaccinated People Are 11 Times More Likely To Die Of COVID-19, New Research Finds – NPR

Original study: Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter

 

Management of high-risk pulmonary embolism in pregnancy.

15 Sep, 2021 | 08:43h | UTC

Management of high-risk pulmonary embolism in pregnancy – Thrombosis Research

 

Report: Fully vaccinated people account for 1.2% of England’s Covid-19 deaths.

14 Sep, 2021 | 10:07h | UTC

Fully vaccinated people account for 1.2% of England’s Covid-19 deaths – The Guardian

Original Report: Deaths involving COVID-19 by vaccination status, England: deaths occurring between 2 January and 2 July 2021 – Office for National Statistics

 

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

14 Sep, 2021 | 10:08h | UTC

News release: COVID-19 vaccine efficacy does not support boosters for general population, review concludes – The Lancet

Original article: Considerations in boosting COVID-19 vaccine immune responses – The Lancet

Commentaries:

FDA experts among group opposing US booster shot plan – Associated Press

FDA vaccine regulators argue against Covid-19 vaccine boosters in new international review – STAT

Global experts pan wider use of COVID vaccine booster dose – CIDRAP

Expert reaction to viewpoint article on COVID-19 booster vaccines for general populations – Science Media Centre

Boosters Are ‘Not Appropriate’ – Reach Unvaccinated First – Health Policy Watch

Data Doesn’t Support Need for COVID-19 Vaccine Boosters: Experts – HealthDay

In a new review, some F.D.A. scientists and others say boosters aren’t needed for the general population. – The New York Times

 

Covid: Single jab recommended for 12 to 15-year-olds by UK’s top doctors.

14 Sep, 2021 | 10:05h | UTC

Covid: Single jab recommended for 12 to 15-year-olds by UK’s top doctors – BBC

See also: Covid-19: Children aged 12-15 should be offered vaccine, say UK’s chief medical officers – The BMJ

 

Review | The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology.

14 Sep, 2021 | 09:58h | UTC

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology – Nature Medicine

 

Commentary on Twitter

 

M-A: Study shows significant risk of major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism.

14 Sep, 2021 | 08:55h | UTC

Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

Long-term Anticoagulation After Unprovoked VTE: New Insights – TCTMD

Extended Anticoagulation Tied to Major Bleeding Risk – HealthDay

 

Commentary on Twitter

 

ESMO Guideline: Early and locally advanced non-small-cell lung cancer

14 Sep, 2021 | 08:42h | UTC

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy – Annals of Oncology

 

Four factors that increase the risk of vaccinated people getting COVID.

12 Sep, 2021 | 22:02h | UTC

Four factors that increase the risk of vaccinated people getting COVID – The Conversation

Original study: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study – The Lancet Infectious Diseases

 

What’s the evidence for COVID-19 booster shots?

12 Sep, 2021 | 22:05h | UTC

What’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal

 

Perspective | We’re Asking the Impossible of Vaccines – “Complete protection against infection has long been hailed as the holy grail of vaccination. It might simply be unachievable”.

12 Sep, 2021 | 21:59h | UTC

We’re Asking the Impossible of Vaccines – The Atlantic

 

Commentary on Twitter

 

Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions.

12 Sep, 2021 | 22:03h | UTC

Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions – CNN

Original study: Hospitalisation among vaccine breakthrough COVID-19 infections – The Lancet Infectious Diseases

News release: Study examines severe breakthrough cases of COVID-19 – YaleNews

 

Commentary on Twitter

 

Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications.

12 Sep, 2021 | 21:46h | UTC

Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications – Intensive Care Medicine

 

Commentary on Twitter

 

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

10 Sep, 2021 | 05:37h | UTC

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial – Nature Medicine

News release: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University

Related:

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.

10 Sep, 2021 | 05:36h | UTC

Face masks for COVID pass their largest test yet – Nature

Original study: [Preprint] Largest study of masks yet details their importance in fighting Covid-19.

 

Commentary on Twitter

 

Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study.

10 Sep, 2021 | 05:33h | UTC

Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study – The BMJ

Original study: Kidney Outcomes in Long COVID – Journal of the American Society of Nephrology

 

Long COVID and kidney disease.

10 Sep, 2021 | 05:31h | UTC

Long COVID and kidney disease – Nature Reviews Nephrology

 

COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.

10 Sep, 2021 | 05:29h | UTC

COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it – The Conversation

Original study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.

 

Perspective | What we actually know about waning immunity.

10 Sep, 2021 | 05:26h | UTC

What We Actually Know About Waning Immunity – The Atlantic

 

Topic-based, recent literature review on pulmonary hypertension.

10 Sep, 2021 | 05:06h | UTC

Topic-Based, Recent Literature Review on Pulmonary Hypertension – Mayo Clinic Proceedings

 

[Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera.

9 Sep, 2021 | 10:02h | UTC

Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera – bioRxiv

Related: United States boosts tracking of coronavirus strains as Mu variant draws scrutiny – Science

 

Commentary on Twitter (thread – click for more)

 

[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.

9 Sep, 2021 | 09:55h | UTC

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv

 

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1435720202147143680

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.